Is Novavax, Inc. (NVAX) a Buy, Sell, or Hold?
Novavax, Inc.
NASDAQ:NVAX
$8.42 USD
-$0.49 (-5.5%)
- Volume
- 3.8M
- Average Volume
- 4.86M
- Market Capitalization
- $1.38B
- P/E Ratio
- -15.59
- Dividend Yield
- 0.00%
- Price Target
- $18.00
- Year High
- $11.97
- Year Low
- $6.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.48
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | John Charles Jacobs |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NVAX |
| CUSIP | 670002401 |
| CIK | 0001000694 |
| Web | https://www.novavax.com |
| Phone | 240 268 2000 |
| Currency | USD |
| Employees | 749 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -2.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.48 |
| Quick Ratio | 2.45 |
| Cash Ratio | 0.67 |
Sales & Book Value
| Annual Sales | $1.12B |
| Price / Sales | 2.32 |
| Cash Flow | -0.60 |
| Price / Cash Flow | -14.25 |
| Price / Book | -9.50 |
Price Target and Rating
| Average Stock Price Forecast | $18.00 |
| High Stock Price Forecast | $25.00 |
| Low Stock Price Forecast | $11.00 |
| Forecast Upside/Downside | -53.22% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 23 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.54 |
| Trailing P/E Ratio | -15.59 |
| PEG Ratio | 0.13 |
| P/E Growth | 0.13 |
| Net Income | $440.3M |
| Net Margin | -14.73% |
| Pretax Margin | -14.45% |
| Return on Equity | 89.73% |
| Return on Assets | -8.42% |
Financials Score
| AltmanZ Score | -4.48 |
| Piotroski Score | 1.00 |
| Working Capital | 508.36M |
| Total Assets | 1.04B |
| Ebit | -64.46M |
| Market Cap | 1.41B |
| Total Liabilities | 1.19B |
Poll Results
About Novavax, Inc. (NASDAQ:NVAX) Stock
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the developmen ... t, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
2026-07-14 18:45:33
In the latest trading session, Novavax (NVAX) closed at $8.42, marking a -5.5% move from the previous day.
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
2026-07-08 18:46:21
Novavax (NVAX) concluded the recent trading session at $9.35, signifying a -1.16% move from its prior day's close.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
2026-07-07 10:01:10
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
2026-06-24 18:47:15
In the closing of the recent trading day, Novavax (NVAX) stood at $8.9, denoting a -1.17% move from the preceding trading day.
Shah Capital Responds to Significant Shareholder Dissent at Novavax AGM
2026-06-24 08:00:00
RALEIGH, N.C., June 24, 2026 (GLOBE NEWSWIRE) -- Shah Capital, the largest shareholder of Novavax, today commented on yesterday's announced voting results from Novavax's June 18th 2026 Annual Meeting of Stockholders.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
2026-06-23 10:01:04
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-06-18 18:46:10
Novavax (NVAX) closed the most recent trading day at $9.13, moving 3.89% from the previous trading session.
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
2026-06-16 15:21:15
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again.
Frequently Asked Questions
-
What is the current Novavax, Inc. (NVAX) stock price?
-
Novavax, Inc.(NASDAQ:NVAX) stock price is $8.42 in the last trading session. During the trading session, NVAX stock reached the peak price of $11.97 while $6.2 was the lowest point it dropped to. The percentage change in NVAX stock occurred in the recent session was --5.5% while the dollar amount for the price change in NVAX stock was -$-0.49.
-
NVAX's industry and sector of operation?
-
The NASDAQ listed NVAX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NVAX?
-
John Charles Jacobs | President, Chief Executive Officer & Director
Erika S. Trahan | Associate Director of Investor & Public Relations
Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden
Richard Crowley | Executive Vice President & Chief Operating Officer
Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer -
How many employees does NVAX have?
-
Number of NVAX employees currently stands at 749. NVAX operates from 21 Firstfield Road, Gaithersburg, MD 20878, US.
-
Link for NVAX official website?
-
Official Website of NVAX is: https://www.novavax.com
-
How do I contact NVAX?
-
NVAX could be contacted at phone #240 268 2000 and can also be accessed through its website. NVAX operates from 21 Firstfield Road, Gaithersburg, MD 20878, US.
-
How many shares of NVAX are traded daily?
-
The average number of NVAX shares traded daily for last 3 months was 4.86M.
-
What is the market cap of NVAX currently?
-
The market value of NVAX currently stands at $1.38B with its latest stock price at $8.42